Agenus (AGEN) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
TipRanksNov 25 01:10 ET · Ratings
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $11
Moomoo NewsNov 19 03:36 ET · Ratings
B. Riley Adjusts Agenus Price Target to $11 From $18, Maintains Buy Rating
MT NewswiresNov 18 08:49 ET · Ratings
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Zacks Nov 15 08:40 ET
Agenus | 10-Q: Q3 2024 Earnings Report
SECNov 12 17:04 ET · Announcements
Agenus Is Maintained at Neutral by HC Wainwright & Co.
Dow JonesNov 12 11:13 ET · Ratings

Comments

Martin J

Nov 22 10:50

🚀🚀🚀

Share Your Profit/Loss

6

2

Jaguar8

Nov 7 09:02

NEWS

$Agenus (AGEN.US)$
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstr...

1

Jaguar8

Sep 13 10:46

NEWS

$Agenus (AGEN.US)$
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Managea...

Trytosaveabit

Sep 9 14:14

Hehehe! They going to fudge the results at today’s conference?

$Agenus (AGEN.US)$ Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results
MT Newswires· 10 mins ago
Agenus (AGEN) is being accused of misleading investors in public comments about a combination of two prospective treatments for cancer in a new shareholder suit filed last week in federal court in Massachusetts.
The Boston-area biotech company has been working to develop several new immuno...

4

Jaguar8

Sep 9 06:34

NEWS

$Agenus (AGEN.US)$
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients wit...

AGEN Agenus

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target